drugset / Trial / NCT04824937
Telaglenastat + Talazoparib In Prostate Cancer
Phase 2
Unknown
30 enrolled
Massachusetts General Hospital
Calithera Biosciences, Inc · collabPfizer · collabProstate Cancer Foundation · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this research is to test the effectiveness of an experimental drug combination for people with metastatic castration-resistant prostate cancer (mCRPC). The names of the study drugs involved in this study are: * Telaglenastat (CB-839) * Talazoparib
Timeline
- Start
- 2021-07
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB-839 | Unknown | — | Oral |
| Subject | Talazoparib | Small molecule | — | Oral |